<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">lvrach</journal-id><journal-title-group><journal-title xml:lang="ru">Лечащий Врач</journal-title><trans-title-group xml:lang="en"><trans-title>Lechaschi Vrach</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1560-5175</issn><issn pub-type="epub">2687-1181</issn><publisher><publisher-name>ООО «Издательство "Открытые системы"»</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.51793/OS.2025.28.4.002</article-id><article-id custom-type="elpub" pub-id-type="custom">lvrach-1384</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>НЕВРОЛОГИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>NEUROLOGY</subject></subj-group></article-categories><title-group><article-title>Болезнь Галлервордена — Шпатца: клиническое наблюдение</article-title><trans-title-group xml:lang="en"><trans-title>Hallerworden — Spatz disease: clinical observation</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8469-1635</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Новикова</surname><given-names>Л. Б.</given-names></name><name name-style="western" xml:lang="en"><surname>Novikova</surname><given-names>L. B.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Новикова Лилия Бареевна - д.м.н., профессор, заведующая кафедрой неврологии и нейрореабилитации.</p><p>450000, Уфа, ул. Ленина 3</p></bio><bio xml:lang="en"><p>Lilia B. Novikova - Dr. of Sci. (Med.), Professor, Head of the Department of Neurology and Neurorehabilitation, Federal State Budgetary Educational Institution of Higher Education Bashkir State Medical University.</p><p>3 Lenina Str., Ufa, 450000</p></bio><email xlink:type="simple">nevrolIDPO@bashgmu.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8552-6233</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Зюльцле</surname><given-names>К. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Ziultsle</surname><given-names>K. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Зюльцле Карина Маратовна - к.м.н., доцент кафедры неврологии и нейрореабилитации.</p><p>450000, Уфа, ул. Ленина, 3</p></bio><bio xml:lang="en"><p>Karina M. Ziultsle - Cand. of Sci. (Med.), Associate Professor of the Department of Neurology and Neurorehabilitation, Federal State Budgetary Educational Institution of Higher Education Bashkir State Medical University.</p><p>3 Lenina Str., Ufa, 450000</p></bio><email xlink:type="simple">sharapovakarina.2020@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8436-5610</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Акопян</surname><given-names>А. П.</given-names></name><name name-style="western" xml:lang="en"><surname>Akopyan</surname><given-names>A. P.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Акопян Анаит Погосовна - к.м.н., доцент кафедры неврологии и нейрореабилитации.</p><p>450000, Уфа, ул. Ленина, 3</p></bio><bio xml:lang="en"><p>Anait P. Akopyan - Cand. of Sci. (Med.), Associate Professor of the Department of Neurology and Neurorehabilitation, Federal State Budgetary Educational Institution of Higher Education Bashkir State Medical University.</p><p>3 Lenina Str., Ufa, 450000</p></bio><email xlink:type="simple">akopian@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Башкирский государственный медицинский университет</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Bashkir state medical University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>08</day><month>04</month><year>2025</year></pub-date><volume>0</volume><issue>4</issue><fpage>16</fpage><lpage>21</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Новикова Л.Б., Зюльцле К.М., Акопян А.П., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Новикова Л.Б., Зюльцле К.М., Акопян А.П.</copyright-holder><copyright-holder xml:lang="en">Novikova L.B., Ziultsle K.M., Akopyan A.P.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://journal.lvrach.ru/jour/article/view/1384">https://journal.lvrach.ru/jour/article/view/1384</self-uri><abstract><sec><title>Результаты</title><p>Результаты. В статье представлено описание клинического наблюдения редкой наследственной болезни Галлервордена – Шпатца (пантотенаткиназа-ассоциированная нейродегенерация, или нейродегенерация с накоплением железа в головном мозге) с атипичной поздней формой в терминальной стадии с дебютом на четвертом десятилетии жизни с быстропрогрессирующим течением и летальным исходом. Наиболее характерными признаками заболевания у данной пациентки были синдром паркинсонизма, выраженная постуральная неустойчивость, пирамидная недостаточность, различные виды гиперкинезов, снижение когнитивных функций, депрессия. При обосновании диагноза опирались на характерную клиническую картину и типичные МРТ-признаки в виде симптома глаза тигра (симметричная гиперинтенсивная зона в области бледного шара внутри более обширной гипоинтенсивной зоны). Поздние случаи необходимо дифференцировать с такими заболеваниями, как болезнь Паркинсона, болезнь с тельцами Леви, болезнь Вильсона – Коновалова, болезнь Фара, болезнь Гентингтона, нейроферритинопатия и другие. В связи с отсутствием в настоящее время эффективных методов лечения пациентка получала симптоматическое лечение, так как этиологическая и патогенетическая терапия этого заболевания отсутствует.</p></sec><sec><title>Заключение</title><p>Заключение. Текущий стандарт медицинской помощи направлен на симптоматическое лечение (агонисты дофаминовых рецепторов или амантадины, антихолинэстеразные и бензодиазепиновые препараты, миорелаксанты, ботулотоксин). Используются также хирургические методы лечения, такие как глубокая стимуляция мозга, абляционная паллидотомия, таламотомия. Необходимо повышать осведомленность неврологов о наличии данной редкой формы нейродегенеративного заболевания с клиникой паркинсонизма в связи с наличием других нозологических форм паркинсонизма-плюс. Своевременная диагностика болезни Галлервордена – Шпатца позволит уже на ранних стадиях назначать соответствующую многообразным проявлениям болезни симптоматическую терапию для повышения качества пациентов больных и снижения медико-экономических затрат.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Results</title><p>Results. The article describes a clinical observation of a rare hereditary Hallervorden – Spatz disease (pantothenate kinase-associated neurodegeneration or neurodegeneration with iron accumulation in the brain) with an atypical late form in the terminal stage with a debut in the fourth decade of life with a rapidly progressive course and a fatal outcome. The most characteristic signs of the disease in this patient were Parkinsonism syndrome, severe postural instability, pyramidal insufficiency, various types of hyperkinesis, decreased cognitive functions, and depression. When substantiating the diagnosis, we relied on the characteristic clinical picture and typical MRI signs in the form of the tiger's eye symptom (a symmetrical hyperintense zone in the region of the pale globe within a larger hypointense zone). Late cases should be differentiated from such diseases as Parkinson's disease, Lewy body disease, Wilson – Konovalov disease, Fahr disease, Huntington's disease, neuroferritinopathy and others. Due to the current lack of effective treatment methods, the patient received symptomatic treatment, since there is no etiologic and pathogenetic therapy for this disease.</p></sec><sec><title>Conclusion</title><p>Conclusion. The current standard of care is aimed at symptomatic treatment (dopamine agonists or amantadines, anticholinesterase drugs, benzodiazepines, muscle relaxants, botulinum toxin). Surgical treatment methods such as deep brain stimulation, ablative pallidotomy, thalamotomy are also used. It is necessary to increase the awareness of neurologists about the presence of this rare form of neurodegenerative disease with the clinic of parkinsonism due to the presence of other nosological forms of parkinsonism-plus. Early diagnosis of Hallervorden – Spatz disease will allow symptomatic therapy to be prescribed at early stages, corresponding to the various manifestations of the disease, to improve the quality of life of patients and reduce medical and economic costs.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>болезнь Галлервордена – Шпатца</kwd><kwd>нейродегенерация</kwd><kwd>паркинсонизм</kwd><kwd>симптом глаза тигра</kwd><kwd>отложение железа</kwd></kwd-group><kwd-group xml:lang="en"><kwd>Hallervorden – Spatz disease</kwd><kwd>neurodegeneration</kwd><kwd>parkinsonism</kwd><kwd>eye of the tiger symptom</kwd><kwd>iron deposition</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Kolarova H., Tan J., Strom T. M., Meitinger T., Wagner M., Klopstock T. Lifetime risk of autosomal recessive neurodegeneration with brain iron accumulation (NBIA) disorders calculated from genetic databases. EBioMedicine. 2022; 77: 103869. DOI: 10.1016/j.ebiom.2022.103869.</mixed-citation><mixed-citation xml:lang="en">Kolarova H., Tan J., Strom T. M., Meitinger T., Wagner M., Klopstock T. Lifetime risk of autosomal recessive neurodegeneration with brain iron accumulation (NBIA) disorders calculated from genetic databases. EBioMedicine. 2022; 77: 103869. DOI: 10.1016/j.ebiom.2022.103869.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Di Meo I., Tiranti V. Classification and molecular pathogenesis of NBIA syndromes. Eur J Paediatr Neurol. 2018; 22 (2): 272-284. DOI: 10.1016/j.ejpn.2018.01.008.</mixed-citation><mixed-citation xml:lang="en">Di Meo I., Tiranti V. Classification and molecular pathogenesis of NBIA syndromes. Eur J Paediatr Neurol. 2018; 22 (2): 272-284. DOI: 10.1016/j.ejpn.2018.01.008.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Huang Y., Wan Z., Tang Y., Xu J., Laboret B., Nallamothu S., Yang C., Liu B., Lu R. O., Lu B., Feng J., Cao J., Hayflick S., Wu Z., Zhou B. Pantothenate kinase 2 interacts with PINK1 to regulate mitochondrial quality control via acetyl-CoA metabolism. Nat Commun. 2022; 13 (1): 2412. DOI: 10.1038/s41467-022-30178-x.</mixed-citation><mixed-citation xml:lang="en">Huang Y., Wan Z., Tang Y., Xu J., Laboret B., Nallamothu S., Yang C., Liu B., Lu R. O., Lu B., Feng J., Cao J., Hayflick S., Wu Z., Zhou B. Pantothenate kinase 2 interacts with PINK1 to regulate mitochondrial quality control via acetyl-CoA metabolism. Nat Commun. 2022; 13 (1): 2412. DOI: 10.1038/s41467-022-30178-x.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Nassif D., Pereira J. S., Spitz M., Capitão C., Faria A. Neurodegeneration with brain iron accumulation: A case report. Dement Neuropsychol. 2016; 10 (2): 160-164. DOI: 10.1590/S1980-5764-2016DN1002014.</mixed-citation><mixed-citation xml:lang="en">Nassif D., Pereira J. S., Spitz M., Capitão C., Faria A. Neurodegeneration with brain iron accumulation: A case report. Dement Neuropsychol. 2016; 10 (2): 160-164. DOI: 10.1590/S1980-5764-2016DN1002014.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Hayflick S. J., Kurian M. A., Hogarth P. Neurodegeneration with brain iron accumulation. Handb Clin Neurol. 2018; 147: 293-305. DOI: 10.1016/B978-0-444-63233-3.00019-1.</mixed-citation><mixed-citation xml:lang="en">Hayflick S. J., Kurian M. A., Hogarth P. Neurodegeneration with brain iron accumulation. Handb Clin Neurol. 2018; 147: 293-305. DOI: 10.1016/B978-0-444-63233-3.00019-1.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Voges L., Kupsch A. Renaming of Hallervorden-Spatz disease: the second man behind the name of the disease. J Neural Transm (Vienna). 2021; 128 (11): 1635-1640. DOI: 10.1007/s00702-021-02408-x.</mixed-citation><mixed-citation xml:lang="en">Voges L., Kupsch A. Renaming of Hallervorden-Spatz disease: the second man behind the name of the disease. J Neural Transm (Vienna). 2021; 128 (11): 1635-1640. DOI: 10.1007/s00702-021-02408-x.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Munshi M. I., Yao S. J., Ben Mamoun C. Redesigning therapies for pantothenate kinase-associated neurodegeneration. J Biol Chem. 2022; 298 (3): 101577. DOI: 10.1016/j.jbc.2022.101577.</mixed-citation><mixed-citation xml:lang="en">Munshi M. I., Yao S. J., Ben Mamoun C. Redesigning therapies for pantothenate kinase-associated neurodegeneration. J Biol Chem. 2022; 298 (3): 101577. DOI: 10.1016/j.jbc.2022.101577.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Аутлев К. М.., Кручинин Е. В., Козлов М. В., Мокин Е. А. и др. Наследственные нейродегенерации с накоплением железа в мозге (литературный обзор). Уральский медицинский журнал. 2019; 3 (171): 9-16.</mixed-citation><mixed-citation xml:lang="en">Autlev K. M., Kruchinin E. V., Kozlov M. V., Mokin E. A. and others. Hereditary neurodegenerations with iron accumulation in the brain (literature review). Ural Medical Journal. 2019; 3 (171): 9-16. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Shi X., Zheng F., Ye X., Li X., Zhao Q., Lin Z., Hu Y., Wang J. Basal ganglia calcification and novel compound heterozygous mutations in the PANK2 gene in a Chinese boy with classic Pantothenate kinase-associated neurodegeneration: A case report. Medicine (Baltimore). 2018; 97 (15): e0316. DOI: 10.1097/MD.0000000000010316.</mixed-citation><mixed-citation xml:lang="en">Shi X., Zheng F., Ye X., Li X., Zhao Q., Lin Z., Hu Y., Wang J. Basal ganglia calcification and novel compound heterozygous mutations in the PANK2 gene in a Chinese boy with classic Pantothenate kinase-associated neurodegeneration: A case report. Medicine (Baltimore). 2018; 97 (15): e0316. DOI: 10.1097/MD.0000000000010316.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Shalash A. S., Rösler T. W., Abdelrahman I. Y., Abulmakarem H. S., Müller S. H., Hopfner F., Kuhlenbäumer G., Höglinger G. U., Salama M. Atypical pantothenate kinase-associated neurodegeneration with variable phenotypes in an Egyptian family. Heliyon. 2021; 7 (7): e07469. DOI: 10.1016/j.heliyon.2021.e07469.</mixed-citation><mixed-citation xml:lang="en">Shalash A. S., Rösler T. W., Abdelrahman I. Y., Abulmakarem H. S., Müller S. H., Hopfner F., Kuhlenbäumer G., Höglinger G. U., Salama M. Atypical pantothenate kinase-associated neurodegeneration with variable phenotypes in an Egyptian family. Heliyon. 2021; 7 (7): e07469. DOI: 10.1016/j.heliyon.2021.e07469.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Marshall R. D., Collins A., Escolar M. L., Jinnah H. A., Klopstock T., Kruer M. C., Videnovic A., Robichaux-Viehoever A., Burns C., Swett L. L., Revicki D. A., Bender R. H., Lenderking W. R. Diagnostic and clinical experience of patients with pantothenate kinase-associated neurodegeneration. Orphanet J Rare Dis. 2019; 14 (1): 174. DOI: 10.1186/s13023-019-1142-1.</mixed-citation><mixed-citation xml:lang="en">Marshall R. D., Collins A., Escolar M. L., Jinnah H. A., Klopstock T., Kruer M. C., Videnovic A., Robichaux-Viehoever A., Burns C., Swett L. L., Revicki D. A., Bender R. H., Lenderking W. R. Diagnostic and clinical experience of patients with pantothenate kinase-associated neurodegeneration. Orphanet J Rare Dis. 2019; 14 (1): 174. DOI: 10.1186/s13023-019-1142-1.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Brezavar D., Bonnen P. E. Incidence of PKAN determined by bioinformatic and population-based analysis of ~140,000 humans. Mol Genet Metab. 2019; 128 (4): 463-469. DOI: 10.1016/j.ymgme.2019.09.002.</mixed-citation><mixed-citation xml:lang="en">Brezavar D., Bonnen P. E. Incidence of PKAN determined by bioinformatic and population-based analysis of ~140,000 humans. Mol Genet Metab. 2019; 128 (4): 463-469. DOI: 10.1016/j.ymgme.2019.09.002.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Пономарев В. В. Болезнь Галлервордена – Шпатца (Клинический обзор и клиническое наблюдение). Международный неврологический журнал. 2011; 3 (41): 120-124.</mixed-citation><mixed-citation xml:lang="en">Ponomarev V. V. Hallervorden – Spatz disease (Clinical review and clinical observation). International Journal of Neurology. 2011; 3 (41): 120-124. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Копишинская С. В., Макушина С. В., Густов А. В., Паршина Е. В. Пантотенаткиназа-ассоциированная нейродегенерация (Болезнь Галлервордена – Шпатца). Медицинский альманах. 2013; 1 (25): 150-152.</mixed-citation><mixed-citation xml:lang="en">Kopishinskaya S. V., Makushina S. V., Gustov A. V., Parshina E. V. Pantothenate kinase-associated neurodegeneration (Hallervorden-Spatz disease). Medical Almanac. 2013; 1 (25): 150-152. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Razmeh S., Habibi A. H., Orooji M., Alizadeh E., Moradiankokhdan K., Razmeh B. Pantothenate kinase-associated neurodegeneration: clinical aspects, diagnosis and treatments. Neurol Int. 2018; 10 (1): 7516.</mixed-citation><mixed-citation xml:lang="en">Razmeh S., Habibi A. H., Orooji M., Alizadeh E., Moradiankokhdan K., Razmeh B. Pantothenate kinase-associated neurodegeneration: clinical aspects, diagnosis and treatments. Neurol Int. 2018; 10 (1): 7516.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Chang X., Zhang J., Jiang Y., Wang J., Wu Y. Natural history and genotype-phenotype correlation of pantothenate kinase-associated neurodegeneration. CNS Neurosci Ther. 2020; 26: 754-761. https://doi.org/10.1111/cns.13294.</mixed-citation><mixed-citation xml:lang="en">Chang X., Zhang J., Jiang Y., Wang J., Wu Y. Natural history and genotype-phenotype correlation of pantothenate kinase-associated neurodegeneration. CNS Neurosci Ther. 2020; 26: 754-761. https://doi.org/10.1111/cns.13294.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Choayb S., Adil H., Ali Mohamed D., Allali N., Chat L., El Haddad S. Eye of the Tiger Sign in Pantothenate Kinase-Associated Neurodegeneration. Case Rep Radiol. 2021; 2021: 6633217. DOI: 10.1155/2021/6633217.</mixed-citation><mixed-citation xml:lang="en">Choayb S., Adil H., Ali Mohamed D., Allali N., Chat L., El Haddad S. Eye of the Tiger Sign in Pantothenate Kinase-Associated Neurodegeneration. Case Rep Radiol. 2021; 2021: 6633217. DOI: 10.1155/2021/6633217.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Paprocka J., Machnikowska-Sokołowska M., Gruszczyńska K., Emich-Widera E. Neuroimaging of Basal Ganglia in Neurometabolic Diseases in Children. Brain Sci. 2020; 10 (11): 849. DOI: 10.3390/brainsci10110849.</mixed-citation><mixed-citation xml:lang="en">Paprocka J., Machnikowska-Sokołowska M., Gruszczyńska K., Emich-Widera E. Neuroimaging of Basal Ganglia in Neurometabolic Diseases in Children. Brain Sci. 2020; 10 (11): 849. DOI: 10.3390/brainsci10110849.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Перевощикова А. А., Юркина Н. В., Спичак И. И. Клинический случай болезни Галлервордена – Шпатца. Педиатрический вестник Южного Урала. 2022; 2: 92-100.</mixed-citation><mixed-citation xml:lang="en">Perevoshchikova A. A., Yurkina N. V., Spichak I. I. Clinical case of Hallervorden-Spatz disease. Pediatric Bulletin of the Southern Urals. 2022; 2: 92-100. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Белинская В. В., Дутова Т. И. Особенности диагностики болезни Галлервордена – Шпатца (клиническое наблюдение). Вселенная мозга. 2021; 2: 7-9.</mixed-citation><mixed-citation xml:lang="en">Belinskaya V. V., Dutova T. I. Features of diagnosis of Hallervorden-Spatz disease (clinical observation). Universe of the brain. 2021; 2: 7-9. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Rivera D., Roa-Sanchez P., Bidó P., Speckter H., Oviedo J., Stoeter P. Cerebral and cerebellar white matter tract alterations in patients with Pantothenate Kinase-Associated Neurodegeneration (PKAN). Parkinsonism Relat Disord. 2022; 98: 1-6. DOI: 10.1016/j.parkreldis.2022.03.017.</mixed-citation><mixed-citation xml:lang="en">Rivera D., Roa-Sanchez P., Bidó P., Speckter H., Oviedo J., Stoeter P. Cerebral and cerebellar white matter tract alterations in patients with Pantothenate Kinase-Associated Neurodegeneration (PKAN). Parkinsonism Relat Disord. 2022; 98: 1-6. DOI: 10.1016/j.parkreldis.2022.03.017.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Hayflick S. .J, Hartman M., Coryell J., et all. Brain MRI in neurodegeneration with brain iron accumulation with and without PANK2 mutations. AJNR Am J Neuroradiol 2006; 27: 1230-1233.</mixed-citation><mixed-citation xml:lang="en">Hayflick S. .J, Hartman M., Coryell J., et all. Brain MRI in neurodegeneration with brain iron accumulation with and without PANK2 mutations. AJNR Am J Neuroradiol 2006; 27: 1230-1233.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Hogarth P. Neurodegeneration with brain iron accumulation: diagnosis and management. J Mov Disord. 2015; 8 (1): 1-13. DOI: 10.14802/jmd.14034.</mixed-citation><mixed-citation xml:lang="en">Hogarth P. Neurodegeneration with brain iron accumulation: diagnosis and management. J Mov Disord. 2015; 8 (1): 1-13. DOI: 10.14802/jmd.14034.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Sharma L. K., Subramanian C., Yun M. K., Frank M. W., White S. W., Rock C. O., Lee R. E., Jackowski S. A therapeutic approach to pantothenate kinase associated neurodegeneration. Nat Commun. 2018; 9 (1): 4399. DOI: 10.1038/s41467-018-06703-2.</mixed-citation><mixed-citation xml:lang="en">Sharma L. K., Subramanian C., Yun M. K., Frank M. W., White S. W., Rock C. O., Lee R. E., Jackowski S. A therapeutic approach to pantothenate kinase associated neurodegeneration. Nat Commun. 2018; 9 (1): 4399. DOI: 10.1038/s41467-018-06703-2.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Pohane M. R., Dafre R., Sontakke N. G. Diagnosis and Treatment of Pantothenate Kinase-Associated Neurodegeneration (PKAN): A Systematic Review. Cureus. 2023; 15 (9): 46135. DOI: 10.7759/cureus.46135.</mixed-citation><mixed-citation xml:lang="en">Pohane M. R., Dafre R., Sontakke N. G. Diagnosis and Treatment of Pantothenate Kinase-Associated Neurodegeneration (PKAN): A Systematic Review. Cureus. 2023; 15 (9): 46135. DOI: 10.7759/cureus.46135.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Руденская Г. Е., Захарова Е. Ю. Наследственные нейродегенерации с накоплением железа в мозге. Анналы клинической и экспериментальной неврологии. 2013; 4 (7): 51-60.</mixed-citation><mixed-citation xml:lang="en">Rudenskaya G. E., Zakharova E. Yu. Hereditary neurodegenerations with iron accumulation in the brain. Annals of Clinical and Experimental Neurology. 2013; 4 (7): 51-60. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Woo K. A., Kim H. J., Jeon S. H., Park H. R., Park K. W., Lee S. H., Chung S. J., Chae J. H., Paek S. H., Jeon B. Long-Term Outcomes of Deep Brain Stimulation in Pantothenate Kinase-Associated Neurodegeneration-Related Dystonia. J Mov Disord. 2022 Sep; 15 (3): 241-248. DOI: 10.14802/jmd.22002</mixed-citation><mixed-citation xml:lang="en">Woo K. A., Kim H. J., Jeon S. H., Park H. R., Park K. W., Lee S. H., Chung S. J., Chae J. H., Paek S. H., Jeon B. Long-Term Outcomes of Deep Brain Stimulation in Pantothenate Kinase-Associated Neurodegeneration-Related Dystonia. J Mov Disord. 2022 Sep; 15 (3): 241-248. DOI: 10.14802/jmd.22002</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Garcia-Ruiz P. J., Ayerbe J., Vela Desojo L., Feliz C. E., Del Val Fernandez J. Deep brain stimulation for pantothenate kinase-associated neurodegeneration. Case Rep Neurol Med. 2015; 2015: 245735. DOI: 10.1155/2015/245735.</mixed-citation><mixed-citation xml:lang="en">Garcia-Ruiz P. J., Ayerbe J., Vela Desojo L., Feliz C. E., Del Val Fernandez J. Deep brain stimulation for pantothenate kinase-associated neurodegeneration. Case Rep Neurol Med. 2015; 2015: 245735. DOI: 10.1155/2015/245735.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
